Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients.
Adult
Age Factors
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Databases, Genetic
Diagnostic Tests, Routine
Epstein-Barr Virus Infections
/ diagnosis
Female
Herpesvirus 4, Human
/ genetics
Humans
Male
Middle Aged
Morocco
Prognosis
Sex Characteristics
Stomach Neoplasms
/ diagnosis
Survival Analysis
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
03
2021
revised:
07
07
2021
accepted:
09
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
6
1
2022
Statut:
epublish
Résumé
The Cancer Genome Atlas (TCGA) project and Asian Cancer Research Group (ACRG) recently categorized gastric cancer into molecular subtypes. Nevertheless, these classification systems require high cost and sophisticated molecular technologies, preventing their widespread use in the clinic. This study is aimed to generating molecular subtypes of gastric cancer using techniques available in routine diagnostic practice in a series of Moroccan gastric cancer patients. In addition, we assessed the associations between molecular subtypes, clinicopathological features, and prognosis. Ninety-seven gastric cancer cases were classified according to TCGA, ACRG, and integrated classifications using a panel of four molecular markers (EBV, MSI, E-cadherin, and p53). HER2 status and PD-L1 expression were also evaluated. These markers were analyzed using immunohistochemistry (E-cadherin, p53, HER2, and PD-L1), in situ hybridization (EBV and HER2 equivocal cases), and multiplex PCR (MSI). Our results showed that the subtypes presented distinct clinicopathological features and prognosis. EBV-positive gastric cancers were found exclusively in male patients. The GS (TCGA classification), MSS/EMT (ACRG classification), and E-cadherin aberrant subtype (integrated classification) presented the Lauren diffuse histology enrichment and tended to be diagnosed at a younger age. The MSI subtype was associated with a better overall survival across all classifications (TCGA, ACRG, and integrated classification). The worst prognosis was observed in the EBV subtype (TCGA and integrated classification) and MSS/EMT subtype (ACRG classification).
Identifiants
pubmed: 34367379
doi: 10.1155/2021/9980410
pmc: PMC8342151
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9980410Informations de copyright
Copyright © 2021 Jean Paul Nshizirungu et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Br J Cancer. 2011 Jun 28;105(1):38-43
pubmed: 21654677
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
Infect Agent Cancer. 2017 Jul 19;12:41
pubmed: 28814970
Braz J Microbiol. 2012 Jan;43(1):393-404
pubmed: 24031845
Mod Pathol. 2016 Jul;29(7):772-84
pubmed: 27032689
Gastroenterology. 2002 Dec;123(6):1804-11
pubmed: 12454837
Genet Test Mol Biomarkers. 2021 Feb;25(2):116-123
pubmed: 33596142
Gastroenterology. 2009 Sep;137(3):824-33
pubmed: 19445939
Histopathology. 1999 Nov;35(5):477-8
pubmed: 10583566
Cancer Treat Rev. 2018 May;66:15-22
pubmed: 29631196
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Histopathology. 2008 Jun;52(7):797-805
pubmed: 18422971
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Virchows Arch. 2018 Mar;472(3):369-382
pubmed: 29046940
J Gastroenterol Hepatol. 2009 Mar;24(3):354-65
pubmed: 19335785
Histopathology. 1999 May;34(5):410-5
pubmed: 10231415
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
BMC Cancer. 2015 Oct 24;15:782
pubmed: 26498209
Arch Toxicol. 2015 Jun;89(6):899-921
pubmed: 25701956
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
Br J Surg. 2004 Apr;91(4):469-75
pubmed: 15048750
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Histopathology. 1994 Aug;25(2):101-11
pubmed: 7982672
Cancer Manag Res. 2019 Jul 10;11:6397-6410
pubmed: 31372044
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Gut. 2014 Feb;63(2):236-43
pubmed: 23580779
Mol Med Rep. 2020 Aug;22(2):828-840
pubmed: 32468041
J Surg Oncol. 2020 Apr;121(5):804-813
pubmed: 31797380
Mol Clin Oncol. 2015 May;3(3):699-705
pubmed: 26137290
PLoS One. 2019 Dec 2;14(12):e0224812
pubmed: 31790410
J Gastrointest Oncol. 2012 Sep;3(3):251-61
pubmed: 22943016
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Med. 2015 Jan;4(1):75-83
pubmed: 25354498
Int J Cancer. 1996 Jun 21;69(3):184-9
pubmed: 8682585
Am J Surg Pathol. 2017 Jan;41(1):106-115
pubmed: 27819872